Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?

    ... many patients do not derive benefit. There is an urgent clinical need to identify patients with low probability of benefiting from ... therapies in patients with MDS remains a top clinical and a research priority. Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Paroxysmal Nocturnal Hemoglobinuria: A Complement-Mediated Hemolytic Anemia

    ... largely mediated by the alternative pathway of complement. Clinical manifestations result from the lack of specific cell surface ... Complement inhibition strategies are an area of active research. Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies

    ... recognized as a distinct entity with unique biologic and clinical features. This change has created a scientific and clinical research landscape that makes it difficult to discern CMML-specific validated ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Genetics factors associated with myelodysplastic syndromes

    ... miR-125a and MiR-21. Somatic mutations may influence the clinical phenotype but are not included in current prognostic scoring systems. In recent years research has brought new insights into these diseases, but few of the findings ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

    ... can influence life expectancy and treatment tolerance. Clinical trials accounting for the heterogeneity of tumor biology and ... with MDS and AML and highlights future directions for research. Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

    ... conditions and, to some extent, appear to define distinct clinical phenotypes in MDS. The high frequency of mutations in different ... targets of the spliceosome mutations is an active area of research. Emerging data from the study of the MDS transcriptome suggests that ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Overview of myelodysplastic syndromes

    ... by diagnostic entities of world renown as well as by other research groups and individuals to establish a reliable prognostic system. ... subgroups and the role of molecular markers in predicting clinical evolution. Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Genetics of myelodysplastic syndromes: new insights

    ... contribute to disease pathogenesis is an active area of research, with a current focus on which downstream target genes may be ... are sufficiently robust to be incorporated into routine clinical practice at this time. Additional studies will be required to ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes

    ... toxicity and relapse rates is another area of active research. SUMMARY: Sequential switching to the alternative HMA, clinical trials of novel targeted therapies, azacitidine-based combination ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Optimizing hypomethylating agents in myelodysplastic syndromes

    ... will hopefully be modified with future results of ongoing clinical and translational research. Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:14pm.